Product Description: VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD)[1].
Applications: Neuroscience-Neuromodulation
Formula: C23H25O5P
References: [1]McGowan E, et al., Integrative Rare Disease Biomedical Profile based Network Supporting Drug Repurposing, a case study of Glioblastoma. Res Sq [Preprint]. 2023 Apr 18:rs.3.rs-2809689.
CAS Number: 852949-30-5
Molecular Weight: 412.42
Compound Purity: 99.87
Research Area: Cancer; Neurological Disease
Solubility: DMSO : ≥ 100 mg/mL
Target: Thyroid Hormone Receptor